Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World September 11, 2014 Emma Stoye	Pharma sales 'will reach $1 trillion' in 2014 Global sales in the pharmaceutical industry are set to go over the $1 trillion mark this year, according to a report by Thomson Reuters.
IndustryWeek April 1, 2009 Jill Jusko	Flat Forecast for R&D Spending: By The Numbers Companies will shift their focus to new business versus existing business or basic research in 2009.
The Motley Fool April 19, 2006 Brian Gorman	Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge.
IndustryWeek June 23, 2010	By The Numbers -- The Expense of R&D Among U.S.-owned businesses and U.S. affiliates of foreign companies, much of the R&D remained in the United States.
Chemistry World March 25, 2015 Dennis Lendrem	Be careful what you wish for There is a big debate right now in the pharmaceutical industry, and specifically about measuring R&D productivity. It all comes down to a choice of metrics.
The Motley Fool July 21, 2004 Brian Gorman	Novartis Shows the Way It may be a model for other pharmaceutical outfits looking to improve productivity.
Chemistry World October 1, 2008 Victoria Gill	GSK to Cut 850 R&D Jobs GlaxoSmithKline has announced that up to 850 R&D jobs will be cut as it implements its new business strategy.
Pharmaceutical Executive January 21, 2014 Tim Powell	Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way?
IEEE Spectrum December 2007 Hira & Ross	The R&D 100 A company's research budget tells you very little about its prospects.
IndustryWeek May 1, 2008 John Teresko	Metrics Matter The top R&D metric used in 2008 is R&D spending as a percentage of sales.
The Motley Fool April 19, 2004 Ben McClure	Ruminations on R&D Spending on research and development is important. But can it help identify promising investments? It's pretty easy to spot companies that spend a lot of money on R&D. It's another thing to pick companies that translate R&D spending into higher stock prices.
IndustryWeek December 1, 2007 Jill Jusko	Hey Big Spender: By the Numbers A look at R & D spending in 2006.
Information Today October 29, 2015	Thomson Reuters Streamlines Healthcare Industry Analysis Thomson Reuters rolled out the Healthcare Intelligence application for Thomson Reuters Eikon to improve workflow for financial professionals.
Information Today November 11, 2014	Thomson Reuters Announces Top 100 Global Innovators The Intellectual Property & Science business of Thomson Reuters released its 2014 Top 100 Global Innovators list.
Chemistry World December 6, 2012 Andrew Turley	Return on drug R&D dropping The pharma industry is getting less and less return on investment in R&D, according to a report. But the trend seems to be bottoming out and -- on a more positive note -- there are more compounds going into late stage development.
The Motley Fool January 31, 2007 Brian Lawler	You're Only Hurting Yourself, Thailand Thailand's decision to allow generics could do more harm than good. Investors, take note.
Chemistry World May 8, 2012 Helen Carmichael	Pharma firms see mixed fortunes in Quebec Quebec's life sciences and pharmaceutical industry has suffered several blows in 2012, with hundreds of R&D jobs being lost. This comes despite the industry receiving hundreds of millions of dollars in government assistance and favorable tax rates.
Information Today July 2, 2013	Thomson Reuters Offers Clinical Trial Intelligence Solutions These solutions improve clinical trials, speed up product development and release, and help professionals strengthen portfolios and R&D strategy.
Fast Company November 2013	Industrial Research Looks Into the Future, and You Can Too! Step 1: Look at existing trends. In other words, what is the current thinking about the future?
IEEE Spectrum December 2005 Hira & Goldstein	R&D 100 Automakers top the list, drug companies trim back, and telecoms continue to gut their research budgets.
The Motley Fool March 15, 2007 Chuck Saletta	The American Century Is Over As more R&D takes place overseas, the technological advances and profits will follow. So should investors.
IndustryWeek January 1, 2009 Jill Jusko	R&D Spending: By the Numbers While the software industry spends 13.6% on R&D as a percentage of sales, the chemicals and energy sector spends only 1%.
The Motley Fool September 10, 2008 Brian Orelli	Are Drug Companies Being Shortsighted With R&D? Cutting research and development spending could be like playing with fire for pharmaceutical companies.
The Motley Fool October 17, 2007 Tom Taulli	Rodman & Renshaw Clones a Bear The biotech boutique has a shaky public offering.
The Motley Fool January 30, 2007 Brian Lawler	Schering-Plough Pushes Ahead The drugmaker successfully continues with its multi-year turnaround plan. Investors would be smart to take a look at this pharmaceutical turnaround stock before it starts to get noticed again.
Pharmaceutical Executive October 1, 2011 Daniel Vasella	Heart of Success: Patient-Centric R&D Drug discovery must remain a core competency of industry. The future success of individual companies will be tightly linked to success in R&D.
The Motley Fool July 22, 2009 Robert Steyer	Canaries in the Drug Coal Mine Contract research organizations like Pharmaceutical Product Development and ICON reflect an ailing drug industry.
Chemistry World June 11, 2008 James Mitchell Crow	GSK Job Cuts Hit Chemists GlaxoSmithKline is cutting the jobs of hundreds of scientists as it restructures its drug R&D operations.
Bio-IT World December 10, 2002 Jim Hall	21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives.
Chemistry World December 21, 2015 Phillip Broadwith	Is bigger really better? Something that's often glossed over in the aftermath of a pharmaceutical mega-merger is whether savings actually materialize, and at what cost to the future success of the businesses.
Chemistry World October 26, 2011 Maria Burke	Europe risks being outstripped by R&D rivals EU companies are lagging behind in R&D investment compared with major competitors from the US and some Asian economies, according to the European Commission's 2011 EU Industrial R&D Investment Scoreboard.
The Motley Fool January 19, 2007 Selena Maranjian	In R&D, China Is No. 2 China passes Japan in research and development spending. What does this mean to investors?
The Motley Fool February 26, 2011 Brian Orelli	FDA Applications and a Look Ahead It isn't pretty.
Pharmaceutical Executive November 1, 2014 Jill Wechsler	Outrage Grows Over Drug Pricing Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge.
IndustryWeek August 1, 2003 John Teresko	Outsourcing And R&D A global perspective and a knowledge network for acquiring technology will offer companies a competitive advantage.
The Motley Fool March 15, 2004 Ben McClure	More R&D, Please Big tech players up the research and development ante.
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
The Motley Fool February 4, 2008 Chuck Saletta	Best International Stock: Teva Pharmaceutical A quick summary of Israel's Teva Pharmaceutical, the world's largest generic drugmaker.
Chemistry World December 10, 2012 Andrew Turley	EU companies increasing R&D Companies in the EU are increasing their investment in R&D, despite the difficult economic conditions, according to a report from the European Commission that looked at the global top 1500 R&D investors.
IndustryWeek January 1, 2008 Jill Jusko	By What Measure? Research and development efforts cost plenty. Gauging their effectiveness, though, remains a challenge.
Chemistry World August 23, 2012 Simon Campbell	Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.
Pharmaceutical Executive September 1, 2012 Roy F. Waldron	Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector?
Chemistry World March 20, 2008 Richard Van Noorden	UK Drug Firms to Slash Research and Jobs The UK pharmaceutical industry is expecting to cut jobs and investment in R&D following an alarming slump in confidence in the UK market.
Pharmaceutical Executive September 1, 2005 Parker & Amar	Building Blockbusters The most lucrative new drugs are often less glamorous than first-in-class new molecular entities. And they are much less risky.
IndustryWeek April 21, 2010	The Competitive Edge -- Is U.S. R&D Investment Holding Up? Data trends suggest that U.S. dominance of high-technology manufacturing is under pressure.
Chemistry World November 21, 2014 Rebecca Trager	China poised to become top science spender China is on track to become the world's top R&D spender before the end of the decade, according to a new report released by the Organization for Economic Cooperation and Development.
The Motley Fool August 27, 2011 Michael Olsen	Rising Star Buy: More Icon Icon shares might not appreciate tomorrow, and they might decline more before they go up. But here is a rare value: a secular growth story at a stellar valuation.
IndustryWeek September 1, 2006 Jill Jusko	Research & Development: Smarter Spending With limited R&D resources but plenty of new product concepts, manufacturers are learning to focus on affordable product strategies.
Bio-IT World January 21, 2005 Jim Golden	Top 10 Trends for 2005 Pharmacovigilance, compliance, outsourcing, and the CIO's role will be big this year.